Seroquel ANDA

AstraZeneca PLC
28 September 2005


Stock Exchange Announcement

                              SEROQUEL ANDA


AstraZeneca received a notice from Teva Pharmaceuticals USA on September 27,
2005, that Teva has submitted an Abbreviated New Drug Application (ANDA) for
quetiapine fumarate tablets (25mg base) containing a Paragraph IV Certification
(alleging invalidity and non-infringement) with respect to AstraZeneca's US
patent number 4,879,288.  AstraZeneca's US patent number 4,879,288 is listed in
the Orange Book in reference to Seroquel.

AstraZeneca is evaluating Teva's notice, and the company continues to have full
confidence in its intellectual property protecting Seroquel.

AstraZeneca has 45 days within which to commence a patent infringement lawsuit
against the filer of an ANDA that would automatically stay, or bar, the FDA from
approving the ANDA for 30 months (or until an adverse court decision, whatever
may occur earlier).

                                     -Ends-

September 28, 2005

Media Enquiries:
Edel McCaffrey, Tel: [phone]
Steve Brown, Tel: [phone]

Investor Enquiries:
Mina Blair, Tel: [phone]
Jonathan Hunt, Tel:  [phone]
Ed Seage, Tel: [phone]
Jorgen Winroth, Tel + 1 212 579 0506



                      This information is provided by RNS
            The company news service from the London Stock Exchange